Mycoplasma pneumoniae is a respiratory pathogen capable of causing severe
extrapulmonary complications, including the development of autoimmune
diseases such as Guillain-Barré syndrome, systemic lupus erythematosus, and
juvenile dermatomyositis. The pathogenic mechanisms involve molecular
mimicry, activation of Toll-like receptors (TLRs) such as TLR2 and TLR4, and
disruptions in cytokine regulation, including the overproduction of interleukin-
17 (IL-17). Oxidative stress, inflammasome activation, and metabolic alterations
in neutrophils further exacerbate inflammatory and autoimmune responses.
Although the infection is usually not very severe, there is growing evidence that
Mycoplasma pneumonia may be linked to the onset of autoimmune disorders.
This emphasizesthe necessity for more studies on this infection. High levels of
macrolide resistance, especially in Asia, and difficulties with diagnosis
emphasize the need for new approaches to prevention and treatment. Studies
have reported promising results with Qingfei Tongluo Formula (QTF). This
traditional Chinese medicine reduces inflammation and mitigates the risk of
autoimmunization by modulating oxidative stress and the PERK pathway.
Future studies should consider Epstein-Barr virus (EBV) co-infection, which may
synergistically increase the risk of autoimmune disease. The development of
vaccines against M. pneumoniae is an important long-term avenue.
Keywords: Mycoplasma pneumoniae, autoimmunity, autoimmune diseases,
Guillain-Barré syndrome, systemic lupus erythematosus, juvenile
dermatomyositis, autoimmune complications of Mycoplasma pneumoniae
